Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

作者：Gil D. Rabinovici, David S. Knopman, Javier Arbizu, Tammie L.S. Benzinger, Kevin J. Donohoe, Oskar Hansson, Peter Herscovitch, Phillip H. Kuo, Jennifer Hagerty Lingler, Satoshi Minoshima, Melissa Erin Murray, Julie C. Price, Stephen P. Salloway, Christopher J. Weber, María C. Carrillo, Keith A. Johnson · 发表于：Journal of Nuclear Medicine · 年份：2025 · DOI：10.2967/jnumed.124.268756 · 被引用次数：68 · 研究领域：Dementia and Cognitive Impairment Research、Medical Imaging Techniques and Applications、Health Systems, Economic Evaluations, Quality of Life

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. Conclusion: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer’s disease.